<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390609</url>
  </required_header>
  <id_info>
    <org_study_id>CR106946</org_study_id>
    <secondary_id>2015-000155-25</secondary_id>
    <secondary_id>PCI-32765CLL1015</secondary_id>
    <nct_id>NCT02390609</nct_id>
  </id_info>
  <brief_title>A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults</brief_title>
  <official_title>Open-Label, Randomized, Parallel Group, 3- or 4-Way Crossover Bioavailability Study of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relative bioavailability (the extent to which a
      drug or other substance becomes available to the body) of ibrutinib in healthy adults
      following single oral dose administration of suspension and sprinkle formulations under fed
      and fasted conditions compared with capsules under fasted conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know the identity of the intervention), randomized (study
      medication assigned to participants by chance), 3- or 4-way crossover (participants may
      receive different interventions sequentially during the trial), and single-center study of
      ibrutinib. The duration of study will be approximately 67 to 83 days per participant. The
      study consists of 3 parts: Screening (28 days before study commences on Day 1); Open-label
      Treatment (consists of 6 treatments, either Ibrutinib capsule or suspension or sprinkle
      capsule granules under fed or fasted condition), in subsequent 3 periods for Group 1 and 4
      periods for Group 2, each separated with washout period of 7 (plus [+] / minus [-] 2) days;
      and follow up Phase (up to 10 + / - 2 days after last study drug administration). All the
      eligible participants will be randomly assigned to 1 of the 6 (Group 1) or 4 (Group 2)
      treatment sequences. In fasted conditions, study drug will be administered following a
      10-hour overnight fast. In fed conditions, participants will also fast from food for 10
      hours, but will consume a high fat breakfast within a 30-minute period. Study drug will be
      administered 2 hours after the breakfast. Participants will not be allowed to have food until
      4 hours of drug administration. Blood samples will be collected for evaluation of
      pharmacokinetics at pre-dose and post-dose of study treatment. Relative bioavailability of
      Ibrutinib will be evaluated primarily. Participants' safety will be monitored throughout the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The Cmax is the maximum observed plasma concentration of Ibrutinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The Tmax is the time to reach the maximum observed plasma concentration of Ibrutinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC[0-24]) Post Dose of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The AUC (0-24hrs) is the area under the plasma Ibrutinib concentration-time curve from 0 to 24 hours post dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Observed Quantifiable Concentration (AUC [0-last]) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The AUC (0-last) is the area under the plasma Ibrutinib concentration-time curve from time 0 to time of the last observed quantifiable concentration (C[last]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma Ibrutinib concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma Ibrutinib concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed quantifiable concentration and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Area Under the Plasma Concentration-Time Curve Obtained by Extrapolation (%AUC[infinity,ex])</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The %AUC(infinity,ex) is calculated by dividing the difference of AUC(0-infinity) and AUC(0-last) by AUC(0-infinity) and then multiplying by 100, (AUC[0-infinity] - AUC[0-last])*100/AUC[0-infinity].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t[1/2]) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The t(1/2) is defined as 0.693/Lambda (z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (Lambda [z]) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The Lambda (z) determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Coefficient of Determination (r^2 [adjusted])</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The r^2 [adjusted] for the number of points used in the estimation of lambda[z].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>The Frel will be calculated as individual Cmax and AUC treatment ratios (for the comparison of food effect). Calculated as: [(AUC[0-infinity][test]/AUC[0-infinity][ref])*(Dose[ref]/Dose[test])]*100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to Parent Ratio for Maximum Plasma Concentration (Cmax) of Ibrutinib</measure>
    <time_frame>Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose on Day 1 of each period</time_frame>
    <description>Metabolite to parent drug ratio for maximum observed plasma concentration of Ibrutinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Screening up to follow-up (10 plus [+] / minus [-] 2 days after last dose administration)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: Sequence 1 (ABC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 2 (BCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 3 (CAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 4 (ACB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 5 (BAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Sequence 6 (CBA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequence 1 (AFDE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequence 2 (DAEF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequence 3 (EDFA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequence 4 (FEAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment A) [Reference]</intervention_name>
    <description>Participants will receive Ibrutinib 560 milligram (mg) (4*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.</description>
    <arm_group_label>Group 1: Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Group 1: Sequence 2 (BCA)</arm_group_label>
    <arm_group_label>Group 1: Sequence 3 (CAB)</arm_group_label>
    <arm_group_label>Group 1: Sequence 4 (ACB)</arm_group_label>
    <arm_group_label>Group 1: Sequence 5 (BAC)</arm_group_label>
    <arm_group_label>Group 1: Sequence 6 (CBA)</arm_group_label>
    <arm_group_label>Group 2: Sequence 1 (AFDE)</arm_group_label>
    <arm_group_label>Group 2: Sequence 2 (DAEF)</arm_group_label>
    <arm_group_label>Group 2: Sequence 3 (EDFA)</arm_group_label>
    <arm_group_label>Group 2: Sequence 4 (FEAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment B)</intervention_name>
    <description>Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.</description>
    <arm_group_label>Group 1: Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Group 1: Sequence 2 (BCA)</arm_group_label>
    <arm_group_label>Group 1: Sequence 3 (CAB)</arm_group_label>
    <arm_group_label>Group 1: Sequence 4 (ACB)</arm_group_label>
    <arm_group_label>Group 1: Sequence 5 (BAC)</arm_group_label>
    <arm_group_label>Group 1: Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment C)</intervention_name>
    <description>Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.</description>
    <arm_group_label>Group 1: Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Group 1: Sequence 2 (BCA)</arm_group_label>
    <arm_group_label>Group 1: Sequence 3 (CAB)</arm_group_label>
    <arm_group_label>Group 1: Sequence 4 (ACB)</arm_group_label>
    <arm_group_label>Group 1: Sequence 5 (BAC)</arm_group_label>
    <arm_group_label>Group 1: Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment D)</intervention_name>
    <description>Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.</description>
    <arm_group_label>Group 2: Sequence 1 (AFDE)</arm_group_label>
    <arm_group_label>Group 2: Sequence 2 (DAEF)</arm_group_label>
    <arm_group_label>Group 2: Sequence 3 (EDFA)</arm_group_label>
    <arm_group_label>Group 2: Sequence 4 (FEAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment E)</intervention_name>
    <description>Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.</description>
    <arm_group_label>Group 2: Sequence 1 (AFDE)</arm_group_label>
    <arm_group_label>Group 2: Sequence 2 (DAEF)</arm_group_label>
    <arm_group_label>Group 2: Sequence 3 (EDFA)</arm_group_label>
    <arm_group_label>Group 2: Sequence 4 (FEAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment F)</intervention_name>
    <description>Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.</description>
    <arm_group_label>Group 2: Sequence 1 (AFDE)</arm_group_label>
    <arm_group_label>Group 2: Sequence 2 (DAEF)</arm_group_label>
    <arm_group_label>Group 2: Sequence 3 (EDFA)</arm_group_label>
    <arm_group_label>Group 2: Sequence 4 (FEAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed an informed consent document indicating they understand the purpose of and
             procedures required for the study and are willing to participate in the study

          -  If a woman, must not be of childbearing potential: postmenopausal ( greater than [&gt;]
             45 years of age with amenorrhea for at least 2 years, or any age with amenorrhea for
             at least 6 months and a serum follicle stimulating hormone (FSH) &gt;40 International
             units [IU]/ Liter [L]); surgically sterile

          -  If a woman, must have a negative serum Î²-human chorionic gonadotropin (hCG) pregnancy
             test at Screening and a negative urine pregnancy test on Day-1 of the each treatment
             period

          -  If a man who is sexually active with a woman of childbearing potential and has not had
             a vasectomy, must agree to use an adequate contraception method as deemed appropriate
             by the investigator (eg, vasectomy, double-barrier, partner using effective
             contraception) and to not donate sperm during the study and for 3 months after
             receiving the last dose of study drug

          -  Body mass index (BMI; weight [kg]/height^2 [m]^2) between 18 and 30 Kilogram (kg)/
             meter^2 (m^2) (inclusive), and body weight not less than 50 kg

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid
             abnormalities, significant pulmonary disease, including bronchospastic respiratory
             disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below
             60 milliliter [mL]/ minute [min]), thyroid disease, neurologic or psychiatric disease,
             infection, or any other illness that the investigator considers should exclude the
             participant or that could interfere with the interpretation of the study results

          -  Clinically significant abnormal values for hematology, coagulation, clinical
             chemistry, at Screening as deemed appropriate by the investigator

          -  Clinically significant abnormal physical examination, vital signs, or 12 lead
             electrocardiogram (ECG) at Screening as deemed appropriate by the investigator

          -  Use of any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for paracetamol and hormonal replacement therapy within 14 days
             before the first dose of the study drug is scheduled until completion of the study

          -  History of drug or alcohol abuse according to Diagnostic and Statistical Manual of
             Mental Disorders (4th edition) (DSM-IV) criteria within 2 years before Screening or
             positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates,
             opiates, cocaine, cannabinoids, amphetamines, and benzodiazepines) at Screening and
             Day-1 of the each treatment period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Bioavailability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

